Guanhao Biotech Co.,Ltd. (SHE:300238)
China flag China · Delayed Price · Currency is CNY
11.92
+0.22 (1.88%)
Sep 2, 2026, 2:15 PM CST

Guanhao Biotech Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Revenue
361.4387.75377.48404.18377.29488.98
Revenue Growth
-7.01%2.72%-6.60%7.13%-22.84%11.91%
Gross Profit
274.66297.18298.65315.92217.69363.6
Operating Income
21.0630.4635.2639.65-55.0868.16
Net Income
17.1824.3527.4231.01-307.8273.69
Earnings Per Share
0.060.090.100.12-1.160.28
EPS Growth
-37.82%-10.00%-16.67%--55.56%

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Investments
145.76160.6106.78105.14126.28159.31
Total Debt
135.19126.93108.3554.6779.06151.38
Net Cash (Debt)
10.5733.68-1.5750.4747.227.93
Net Cash Growth
-20.69%--6.88%495.52%-
Net Cash Per Share
0.040.12-0.010.200.180.03

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Cash Flow
25.4271.4749.5554.1570.98122.39
Capital Expenditures
-30.36-38.17-76.2-53.92-41.17-4.71
Free Cash Flow
-4.9433.3-26.650.2329.81117.68
Free Cash Flow Growth
----99.22%-74.67%16.59%

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Gross Margin
76.00%76.64%79.12%78.16%57.70%74.36%
Operating Margin
5.83%7.85%9.34%9.81%-14.60%13.94%
Pretax Margin
4.49%7.04%7.42%7.94%-77.55%16.78%
Profit Margin
4.75%6.28%7.26%7.67%-81.59%15.07%
FCF Margin
-1.37%8.59%-7.06%0.06%7.90%24.07%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
PE Ratio
187.53150.84116.44115.96-66.68
Forward PE
-78.3178.3178.3178.3178.31
P/FCF Ratio
-110.27-15555.6291.4441.75
PS Ratio
8.589.478.468.907.2310.05